Application
C. Immunofluorescent staining of HeLa cells using anti-Paxillin (N-term) RabMAb (Cat. #AJ1592a).Application
B. Immunohistochemical analysis of paraffin-embedded breast carcinoma using anti-Paxillin (N-term) RabMAb (Cat. #AJ1592a).Application
A. Western blot analysis on Hela cell lysate using anti-Paxilin (N-term) RabMAb (Cat. #AJ1592a), dilution 1:10,000.| Product Name | Paxillin Antibody (N-term) |
|---|---|
| Antibody Type | Primary Antibodies |
| Antigen Alias | PXN, Paxillin |
| Clonality | Monoclonal |
|---|---|
| Clone Number | Y113 |
| Host Species | Rabbit |
| Tested Applications | IFIHCWB |
| IHC:1:100 WB |
|
| Species Reactivity | Human |
| Concentration | 1mg/ml |
| Alternative Names | PXN Paxillin |
|---|---|
| Molecular Weight(MW) | 64505 Da |
| Function | Cytoskeletal protein involved in actin-membrane attachment at sites of cell adhesion to the extracellular matrix (focal adhesion) |
| Tissue Specificity | A synthetic peptide corresponding to residues in N-terminus of human Paxillin was used as immunogen. This antibody detects alpha, beta and gamma isoforms of Paxillin. |
| Cellular Localization | Cytoplasm, cytoskeleton. Cell junction, focal adhesion. Cytoplasm, cell cortex (By similarity) Note=Colocalizes with integrins at the cell periphery (By similarity) |
| Entrez Gene | 5829 |
|---|
Application
C. Immunofluorescent staining of HeLa cells using anti-Paxillin (N-term) RabMAb (Cat. #AJ1592a).
Application
B. Immunohistochemical analysis of paraffin-embedded breast carcinoma using anti-Paxillin (N-term) RabMAb (Cat. #AJ1592a).
Application
A. Western blot analysis on Hela cell lysate using anti-Paxilin (N-term) RabMAb (Cat. #AJ1592a), dilution 1:10,000.| Application Notes | IHC:1:100 WB |
|---|
| Form | Liquid |
|---|---|
| Storage Instructions | For short-term storage, store at 4° C. For long-term storage, aliquot and store at -20ºC or below. Avoid multiple freeze-thaw cycles. |
| Storage Buffer | 50 mM Tris-Glycine (pH 7.4), 0.15 M NaCl, 40% Glycerol, 0.01% sodium azide and 0.05% BSA. |
